



AtriCure to Present at the Canaccord 35th Annual Growth Conference

July 15, 2015

WEST CHESTER, Ohio--(BUSINESS WIRE)--Jul. 15, 2015-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation and Left Atrial Appendage Management, today announced that it will present at the Canaccord 35th Annual Growth Conference at the Intercontinental Hotel in Boston on Wednesday, August 12, 2015. Management is scheduled to present at 1:00 p.m. Eastern Time. A live audio webcast of the presentation may be accessed by visiting the Investors page of AtriCure's corporate website at www.atricure.com. A replay of the presentation will be available for 90 days following the presentation.

About AtriCure, Inc.

AtriCure, Inc. is a medical device company providing innovative atrial fibrillation (Afib) solutions designed to produce superior outcomes that reduce the economic and social burden of atrial fibrillation. AtriCure's Synergy™ Ablation System is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures. AtriCure's AtriClip left atrial appendage management (LAAM) exclusion device is the most widely sold device worldwide that's indicated for the occlusion of the left atrial appendage. The company believes cardiothoracic surgeons are adopting its ablation and LAAM devices for the treatment of Afib and reduction of Afib related complications such as stroke. Afib affects more than 33 million people worldwide.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20150715006468/en/>

Source: AtriCure, Inc.

AtriCure, Inc.

Andy Wade, 513-755-4564

Senior Vice President and Chief Financial Officer

awade@atricure.com

or

Investor Relations Contact

Westwicke Partners

Lynn Pieper, 415-202-5678

lynn.pieper@westwicke.com